Quando uma patente expira, não se trata apenas de uma mudança jurídica — trata-se de uma redistribuição de poder sobre quem pode acessar o alívio que a medicina promete. No Brasil, a aprovação do Ozivy pela Anvisa em maio de 2026 marca o fim do monopólio da Novo Nordisk sobre a semaglutida, abrindo caminho para que fabricantes nacionais disputem um mercado que combina necessidade médica genuína, fenômeno cultural e bilhões em receita. A EMS tornou-se a primeira empresa brasileira a cruzar esse limiar regulatório, sinalizando que o acesso a tratamentos para diabetes e obesidade pode, com o temp
Brasil 247
· May 26, 2026
· health
· 2 min read
High
Sourcing: Verified
Anvisa aprova Ozivy, primeira semaglutida nacional após patente expirar
◉
Health & Medicine
2808 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Brazil's obesity guidelines shift focus from weight loss to disease ma…
Correio Braziliense · 90% match
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% match
Related Coverage
Diário de Petrópolis · Aug 24
Dengue, zika, chikungunya e Oropouche: diferenças e riscos da automedicação
Arboviroses apresentam sintomas semelhantes mas evoluções distintas; automedicação com anti-inflamatórios pode agravar d…
ZAP Notícias · Aug 23 Proximidade de lavandarias a seco pode aumentar risco de ParkinsonEstudo com dados de Medicare sugere que viver a menos de 152 metros de lavandarias a seco está associado a 14% maior pro…
TVBV ONLINE · Aug 23 Uso inadequado de zolpidem acende alerta sobre riscos do remédio para insôniaEspecialistas alertam sobre riscos do zolpidem, medicamento popular para insônia no Brasil, que pode causar dependência …
en.com.br · Aug 23 Calor extremo em Cuiabá aumenta risco de pedra nos rins sem hidratação adequadaAltas temperaturas em Cuiabá favorecem desidratação e aumentam concentração de substâncias na urina, elevando o risco de…
Bias & Framing
⚖
Article presents Anvisa's approval of domestic semaglutide as market competition news with optimistic framing about price reduction and access expansion.
Bias Direction
center-left
Confidence
MED
Pro-competition/pro-consumer framing emphasizing benefits of market entry and price pressure, with positive language around regulatory approval and access expansion. Frames patent expiration as opening opportunity rather than discussing innovation incentives.
canetas emagrecedoras (weight-loss pens) - colloquial, sensationalized term
disputa pelo mercado (market dispute) - adversarial framing
segmento bilionário (billion-dollar segment) - emphasizes market size/profit
forte procura (strong demand) - implies popularity/desirability
expectativa é que...os preços possam cair (expectation that prices may fall) - optimistic projection
Novo Nordisk's position on generic competition and innovation concerns
Potential concerns about quality/safety of new manufacturers
Cost of regulatory approval process for domestic manufacturers
Intellectual property or innovation incentive discussion
Patient access barriers beyond price (distribution, insurance coverage)
Timeline realism for actual price reductions
Geopolitical Impact
🌎
Brazil's approval of domestic semaglutide (Ozivy) after Novo Nordisk's patent expiration signals market liberalization in GLP-1 drugs, potentially reducing prices and expanding access while reshaping pharmaceutical competition in Latin America's largest economy.
Escalation Risk
low
Confidence
HIGH
Brazil
Latin America
Global pharmaceutical markets
Shift from Novo Nordisk's monopoly to competitive market; strengthens Brazilian pharmaceutical sovereignty and domestic industry (EMS); reduces dependency on Danish multinational; may inspire similar generic/biosimilar approvals across Latin America; positions Brazil as regional pharmaceutical hub for GLP-1 production.
Similar to India's generic drug revolution post-TRIPS flexibilities, enabling domestic manufacturers to capture markets after patent expiration and establish regional pharmaceutical leadership.
Economic Lens
📈
Brazil's approval of EMS's domestic semaglutide (Ozivy) post-patent expiration introduces competition to the GLP-1 market, likely reducing prices and expanding access to diabetes/obesity treatments.
Market Signal
mixed
Confidence
HIGH
Pharmaceuticals & Biotechnology
Healthcare & Medical Services
Consumer Health Products
Public Health Systems
Consumers and patients will benefit from lower medication costs as competition increases, improving access to semaglutide treatments for diabetes and obesity. However, availability may be initially limited as new competitors scale production.
Regulatory approval of biosimilar pathways encourages domestic pharmaceutical development and reduces dependence on foreign monopolies. Government may consider price regulation or subsidy programs to accelerate public access through the health system (SUS).